Fexinidazole

Major

Fexinidazole Acetaminophen And Codeine Capital® & Codeine Explained An increased CYP3A4 substrate exposure Details Fexinidazole Omeprazole Gastrobim Explained An increased CYP3A4 substrate exposure Details Fexinidazole Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Fexinidazole Sertraline Explained An increased risk of QT interval prolongation Details Fexinidazole Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Fexinidazole Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Fexinidazole Colchicine Colcrys Explained An increased CYP3A4 substrate exposure Details Fexinidazole Simvastatin Flolipid Explained An increased CYP3A4 substrate exposure Details Fexinidazole Abemaciclib Verzenio Explained An increased CYP3A4 substrate exposure Details Fexinidazole Acalabrutinib Calquence An increased CYP3A4 substrate exposure Details Fexinidazole Acyclovir Avaclyr Increased exposure of OAT1/OAT3 substrate Details Fexinidazole Acyclovir Injection Avaclyr Increased exposure of OAT1/OAT3 substrate Details Fexinidazole Acyclovir Ophthalmic Avaclyr Increased exposure of OAT1/OAT3 substrate Details Fexinidazole Acyclovir Topical Zovirax Increased exposure of OAT1/OAT3 substrate Details Fexinidazole Amisulpride Injection Barhemsys An increased risk of QT interval prolongation Details Fexinidazole Apixaban Eliquis Explained An increased CYP3A4 substrate exposure Details Fexinidazole Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Fexinidazole Aripiprazole Injection Abilify Increased exposure of CYP3A4 substrate; increased risk of QT interval prolongation and arrhythmias Details Fexinidazole Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Fexinidazole Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Fexinidazole Atenolol Tenormin Explained Increased risk of bradycardia Details Fexinidazole Avapritinib Ayvakit An increased CYP3A4 substrate exposure Details Fexinidazole Avatrombopag Doptelet An increased CYP3A4 substrate exposure Details Fexinidazole Azithromycin AzaSite An increased risk of QT interval prolongation Details Fexinidazole Belumosudil Rezurock Explained An increased CYP3A4 substrate exposure Details Fexinidazole Acebutolol Sectral® Increased risk of bradycardia Details Fexinidazole Atorvastatin Atorvaliq An increased CYP3A4 substrate exposure Details Fexinidazole Abiraterone Abirtega An increased CYP3A4 substrate exposure Details Fexinidazole Alfuzosin UroXatral Increased exposure of CYP3A4 substrate; increased risk of QT interval prolongation and arrhythmias Details Fexinidazole Amlodipine Amvaz® An increased CYP3A4 substrate exposure Details Fexinidazole Anagrelide Agrylin An increased risk of QT interval prolongation Details Fexinidazole Avanafil Stendra An increased CYP3A4 substrate exposure Details Fexinidazole Axitinib Inlyta An increased CYP3A4 substrate exposure Details Fexinidazole Baricitinib Olumiant Increased exposure of OAT1/OAT3 substrate Details Fexinidazole Bedaquiline Sirturo Increased exposure of CYP3A4 substrate; increased risk of QT interval prolongation and arrhythmias Details Fexinidazole Bisoprolol Zebeta® Increased risk of bradycardia Details Fexinidazole Bosutinib Bosulif An increased CYP3A4 substrate exposure Details Fexinidazole Brigatinib Alunbrig An increased CYP3A4 substrate exposure Details Fexinidazole Budesonide Entocort An increased CYP3A4 substrate exposure Details Fexinidazole Budesonide Nasal Spray Rhinocort An increased CYP3A4 substrate exposure Details